Adaptive Deep Brain Stimulation for Parkinson's Disease

(Auto aDBS Trial)

This trial tests a new approach to deep brain stimulation (DBS) for people with Parkinson's disease. Traditional DBS delivers a constant electrical signal to the brain, which can sometimes be excessive or insufficient. The new method, called adaptive DBS, automatically adjusts the signal based on real-time brain activity. This study targets individuals who have undergone DBS surgery but still experience movement problems. Participants should have tried traditional DBS and continue to face issues like ongoing movement fluctuations.

As an unphased trial, this study provides a unique opportunity to explore innovative treatment options that could enhance participants' quality of life.

The trial information does not specify whether you need to stop taking your current medications. However, since the focus is on adjusting deep brain stimulation settings, it's possible that you may continue your current medications unless advised otherwise by the study team.

Research has shown that adaptive deep brain stimulation (aDBS) for Parkinson's disease is generally well-tolerated. Earlier studies found aDBS promising because it adjusts stimulation based on real-time needs, helping to avoid excessive or insufficient stimulation. Reports indicate that patients did not experience more side effects compared to the traditional constant DBS (cDBS) method.

The Medtronic Percept device, used in both aDBS and cDBS, has FDA approval for treating Parkinson's disease, indicating its safety for use in people. This approval suggests that any side effects are manageable and not significantly different from standard treatment methods. Overall, both aDBS and cDBS are considered safe options for managing Parkinson's disease symptoms.

Researchers are excited about the trial for adaptive Deep Brain Stimulation (aDBS) in Parkinson's disease because it offers a tailored approach that automatically adjusts in real-time to the patient's brain signals. Unlike the standard continuous DBS (cDBS), which delivers a constant level of stimulation, aDBS uses clever technology to sense beta-band neural activity and modify the stimulation accordingly. This adaptive method could potentially improve symptom management and reduce side effects by providing just the right amount of stimulation as needed, making it a promising advancement in personalized treatment for Parkinson's disease.

Research has shown that adaptive deep brain stimulation (aDBS), one of the treatments studied in this trial, holds promise for people with Parkinson's disease. Studies have found that aDBS can greatly improve symptoms like tremors, stiffness, and slow movements. This technology adjusts stimulation based on real-time brain signals, better meeting the patient's needs throughout the day. After a month of use, 98% of patients preferred aDBS over traditional methods, highlighting its effectiveness. Long-term studies confirm that aDBS is safe and well-tolerated by patients. Overall, aDBS offers a more personalized and effective way to manage Parkinson's symptoms. Meanwhile, the trial will also evaluate open-loop continuous deep brain stimulation (cDBS) as an active comparator to assess its effectiveness and safety.¹²³⁴⁵